Role of Increased n-acetylaspartate Levels in Cancer.

BACKGROUND The clinical and biological effects of metabolic alterations in cancer are not fully understood. METHODS In high-grade serous ovarian cancer (HGSOC) samples (n = 101), over 170 metabolites were profiled and compared with normal ovarian tissues (n = 15). To determine NAT8L gene expression across different cancer types, we analyzed the RNA expression of cancer types using RNASeqV2 data available from the open access The Cancer Genome Atlas (TCGA) website (http://www.cbioportal.org/public-portal/). Using NAT8L siRNA, molecular techniques and histological analysis, we determined cancer cell viability, proliferation, apoptosis, and tumor growth in in vitro and in vivo (n = 6-10 mice/group) settings. Data were analyzed with the Student's t test and Kaplan-Meier analysis. Statistical tests were two-sided. RESULTS Patients with high levels of tumoral NAA and its biosynthetic enzyme, aspartate N-acetyltransferase (NAT8L), had worse overall survival than patients with low levels of NAA and NAT8L. The overall survival duration of patients with higher-than-median NAA levels (3.6 years) was lower than that of patients with lower-than-median NAA levels (5.1 years, P = .03). High NAT8L gene expression in other cancers (melanoma, renal cell, breast, colon, and uterine cancers) was associated with worse overall survival. NAT8L silencing reduced cancer cell viability (HEYA8: control siRNA 90.61% ± 2.53, NAT8L siRNA 39.43% ± 3.00, P < .001; A2780: control siRNA 90.59% ± 2.53, NAT8L siRNA 7.44% ± 1.71, P < .001) and proliferation (HEYA8: control siRNA 74.83% ± 0.92, NAT8L siRNA 55.70% ± 1.54, P < .001; A2780: control siRNA 50.17% ± 4.13, NAT8L siRNA 26.52% ± 3.70, P < .001), which was rescued by addition of NAA. In orthotopic mouse models (ovarian cancer and melanoma), NAT8L silencing reduced tumor growth statistically significantly (A2780: control siRNA 0.52 g ± 0.15, NAT8L siRNA 0.08 g ± 0.17, P < .001; HEYA8: control siRNA 0.79 g ± 0.42, NAT8L siRNA 0.24 g ± 0.18, P = .008, A375-SM: control siRNA 0.55 g ± 0.22, NAT8L siRNA 0.21 g ± 0.17 g, P = .001). NAT8L silencing downregulated the anti-apoptotic pathway, which was mediated through FOXM1. CONCLUSION These findings indicate that the NAA pathway has a prominent role in promoting tumor growth and represents a valuable target for anticancer therapy.Altered energy metabolism is a hallmark of cancer (1). Proliferating cancer cells have much greater metabolic requirements than nonproliferating differentiated cells (2,3). Moreover, altered cancer metabolism elevates unique metabolic intermediates, which can promote cancer survival and progression (4,5). Furthermore, emerging evidence suggests that proliferating cancer cells exploit alternative metabolic pathways to meet their high demand for energy and to accumulate biomass (6-8).

[1]  J. Moffett,et al.  N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology , 2007, Progress in Neurobiology.

[2]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[3]  Prahlad T. Ram,et al.  NetWalker: a contextual network analysis tool for functional genomics , 2012, BMC Genomics.

[4]  Sham S. Kakar,et al.  Identification of Metabolites in the Normal Ovary and Their Transformation in Primary and Metastatic Ovarian Cancer , 2011, PloS one.

[5]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Anne M. Evans,et al.  Organization of GC/MS and LC/MS metabolomics data into chemical libraries , 2010, J. Cheminformatics.

[7]  Prahlad T. Ram,et al.  Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer , 2014, Molecular systems biology.

[8]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[9]  H. Tallan.  Studies on the distribution of N-acetyl-L-aspartic acid in brain. , 1957, The Journal of biological chemistry.

[10]  C. Bucana,et al.  Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. , 1989, Journal of the National Cancer Institute.

[11]  Liz Y. Han,et al.  Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. , 2006, Journal of the National Cancer Institute.

[12]  N. Pattabiraman,et al.  Methamphetamine-induced neuronal protein NAT8L is the NAA biosynthetic enzyme: Implications for specialized acetyl coenzyme A metabolism in the CNS , 2010, Brain Research.

[13]  Benjamin L. Ebert,et al.  (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.

[14]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[15]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[16]  H. Tallan,et al.  Studies on the free amino acids and related compounds in the tissues of the cat. , 1954, The Journal of biological chemistry.

[17]  P. Courtoy,et al.  Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartia. , 2009, The Biochemical journal.

[18]  M. Ringnér,et al.  Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome , 2010, Clinical Cancer Research.

[19]  Liz Y. Han,et al.  Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. , 2008, Journal of the National Cancer Institute.

[20]  C. Dang,et al.  MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities , 2009, Clinical Cancer Research.

[21]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[22]  Jan-Fang Cheng,et al.  Dicer, Drosha, and outcomes in patients with ovarian cancer. , 2008, The New England journal of medicine.

[23]  M. Milburn,et al.  Analysis of the adult human plasma metabolome. , 2008, Pharmacogenomics.

[24]  Dirk Repsilber,et al.  Biomarkers of Inflammation, Immunosuppression and Stress Are Revealed by Metabolomic Profiling of Tuberculosis Patients , 2012, PloS one.

[25]  Sean M. Hartig,et al.  Nitric oxide is a positive regulator of the Warburg effect in ovarian cancer cells , 2014, Cell Death and Disease.

[26]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[27]  Christopher Nimsky,et al.  Differences in metabolism of fiber tract alterations in gliomas: a combined fiber density mapping and magnetic resonance spectroscopic imaging study. , 2012, Neurosurgery.

[28]  A. Klopp,et al.  Nitric oxide mediates metabolic coupling of omentum-derived adipose stroma to ovarian and endometrial cancer cells. , 2015, Cancer research.

[29]  V. Vacic,et al.  Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival , 2009, Proceedings of the National Academy of Sciences.

[30]  H. Christofk,et al.  Rapidly Proliferating Cells Evidence for an Alternative Glycolytic Pathway in , 2010 .

[31]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[32]  M. Zeng,et al.  Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results , 2012, La radiologia medica.

[33]  F. Moussallieh,et al.  Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy , 2011, Journal of oncology.

[34]  Liz Y. Han,et al.  Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma , 2006, Nature Medicine.

[35]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[36]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[37]  이연수.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[38]  G. Calin,et al.  Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.

[39]  Susan M. Chang,et al.  Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. , 2013, Neuro-oncology.